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Converting a vaccine into a thermostable dry powder is advantageous as it reduces the
resource burden linked with the cold chain and provides ﬂexibility in dosage and
administration through different routes. Such a dry powder presentation may be
especially useful in the development of a vaccine towards the respiratory infectious
disease tuberculosis (TB). This study assesses the immunogenicity and protective
efﬁcacy of spray-dried ID93+GLA-SE, a promising TB vaccine candidate, against
Mycobacterium tuberculosis (Mtb) in a murine model when administered via different
routes. Four administration routes for the spray-dried ID93+GLA-SE were evaluated along
with relevant controls—1) reconstitution and intramuscular injection, 2) reconstitution and
intranasal delivery, 3) nasal dry powder delivery via inhalation, and 4) pulmonary dry
powder delivery via inhalation. Dry powder intranasal and pulmonary delivery was achieved
using a custom nose-only inhalation device, and optimization using representative
vaccine-free powder demonstrated that approximately 10 and 44% of the maximum
possible delivered dose would be delivered for intranasal delivery and pulmonary delivery,
respectively. Spray-dried powder was engineered according to the different administration
routes including maintaining approximately equivalent delivered doses of ID93 and GLA.
Vaccine properties of the different spray-dried lots were assessed for quality control in
terms of nanoemulsion droplet diameter, polydispersity index, adjuvant content, and
antigen content. Our results using the Mtb mouse challenge model show that both
intranasal reconstituted vaccine delivery as well as pulmonary dry powder vaccine
delivery resulted in Mtb control in infected mice comparable to traditional intramuscular
delivery. Improved protection in these two vaccinated groups over their respective control
groups coincided with the presence of cytokine-producing T cell responses. In summary,
our results provide novel vaccine formulations and delivery routes that can be harnessed to
provide protection against Mtb infection.
Keywords: dry powder vaccine, respiratory delivery, in vivo murine model, nose-only inhalation device, particle
engineering, vaccine adjuvant formulation, tuberculosis, ID93+GLA-SE
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INTRODUCTION

least in part due to induction of more effective mucosal
immune responses (Derrick et al., 2014; Grifﬁths et al., 2016a;
Ahmed et al., 2017a; Ahmed et al., 2017b; Raeven et al., 2018;
Vierboom et al., 2021). Given the potential beneﬁts of respiratory
administration, an inhalable presentation of the spray-dried
ID93+GLA-SE powder designed for pulmonary delivery was
developed (Gomez et al., 2021b). The study established a lead
inhalable excipient system consisting of trehalose and small
amounts of the tripeptide trileucine. The spray-dried inhalable
presentation of ID93+GLA-SE showed promising thermostability
over 1 year of storage (Gomez et al., 2021c). While these results
are encouraging, in vivo preclinical testing is necessary to assess
safety and immunogenicity prior to testing with humans.
Mice are commonly used for preclinical trials because of their
small size, low maintenance cost, and short growth time, all of
which allow for many to be tested at one time for statistical
validity (Nadithe et al., 2003; Cryan et al., 2007). Several methods
of aerosol delivery have been developed expressly for the murine
respiratory system as it is often not feasible to deliver aerosols
using human clinical inhalation devices. For example, nose-only
exposure systems, wherein mice are restrained in tubes against
noseports, have been successfully used in rodent inhalation
studies (Wang et al., 2014; Verco et al., 2018; Carrigy et al.,
2019). These aerosol delivery systems are generally comprised of
two main components: a device to aerosolize the liquid or dry
product, and a nose-only exposure system to restrain the mice.
The aerosolization of dry products through dispersion of a dry
powder can be accomplished through several methods, such as
the use of a dust generator (Wang et al., 2014; Chand et al., 2016;
Cosnier et al., 2016). Spray drying of ID93+GLA-SE has shown
promising results as a thermostable and inhalable presentation.
However, previous work evaluated the spray-dried product
through biochemical assays and not with an in vivo model.
Furthermore, these studies did not test for the optimal method
of administration. In the present study, administration of spraydried ID93+GLA-SE through different routes was evaluated in a
murine model, including intramuscular injection, intranasal
liquid delivery, intranasal powder delivery, and pulmonary
powder delivery. Particle engineering was used to design
powder suitable for each method of administration. Powder
inhalation was completed using a custom aerosol delivery
device. This device was characterized and optimized prior to
conducting the study. The murine studies consisted of
immunogenicity studies comparing the immune response
induced by the different routes and protective efﬁcacy studies
wherein the mice were challenged with Mycobacterium
tuberculosis (Mtb) after immunization and bacterial burden
was compared for the different routes.

Tuberculosis (TB) is a highly infectious respiratory disease that
was responsible for the deaths of 1.2 million people worldwide in
2019 (WHO, 2020). There has been a rise in drug-resistant
strains, with approximately 500,000 people developing drugresistant TB in 2019 (WHO, 2020). The increased risk posed
by these strains illustrates the need for effective prevention
programs. However, the Bacille Calmette-Guerin (BCG)
vaccine, the only licensed TB vaccine, provides variable
efﬁcacy in preventing TB in adults (Dockrell and Smith, 2017;
WHO, 2020). Thus, several new TB vaccine candidates have been
investigated as alternatives. For instance, the M72/AS01E TB
vaccine consisting of a recombinant fusion protein antigen
with a liposome adjuvant system containing a naturally
derived Toll-like receptor 4 ligand and a saponin reduced
disease progression after 3 years by 49.7% in Phase 2 clinical
testing (Tait et al., 2019). Another promising candidate is the
ID93+GLA-SE vaccine developed by the Infectious Disease
Research Institute. ID93+GLA-SE is a subunit vaccine that
consists of an antigen, ID93, and an adjuvant system, GLA-SE,
that consists of a synthetic Toll-like receptor 4 ligand formulated
in a nanoemulsion (Bertholet et al., 2010; Coler et al., 2018; PennNicholson et al., 2018). The ID93+GLA-SE vaccine candidate is
currently undergoing Phase II clinical trials as a liquid injectable
presentation (ClinicalTrials.gov, 2019; Day et al., 2021). Like
many other vaccines, the liquid dosage form requires
refrigeration to maintain potency, and therefore widespread
global vaccine rollouts may be hindered by the resource
burden associated with maintaining the cold chain.
Conversion of a liquid product into a thermostable dry form
may improve distribution. Previously, we developed a
thermostable lyophilized presentation of ID93+GLA-SE
designed for reconstitution prior to injection, and it is
currently undergoing Phase 1 clinical evaluation (Kramer
et al., 2018). Another method of desiccation is through spray
drying, wherein an atomized liquid product is dried into a
powder. Spray drying has been shown to successfully confer
thermostability to several experimental vaccines (Kanojia et al.,
2018; LeClair et al., 2019) and approved vaccines (Kunda et al.,
2019; Price et al., 2020).
Spray drying the ID93+GLA-SE into a thermostable dry
powder form has been explored previously. Initially, the
ID93+GLA-SE formulation was spray-dried into a powder
designed for eventual reconstitution using the disaccharide
trehalose as a stabilizing excipient (Gomez et al., 2021a). This
presentation demonstrated promising long-term room
temperature stability and short-term high temperature
stability. While parenteral injection is the most common
method of administration for vaccines, administration through
inhalation has been gathering more attention. Inhalable routes
allow for high-dose targeting at the site of infection while
minimizing possible systemic toxic effects (Hickey et al.,
2016). Additionally, immunization studies on mice and
nonhuman primates have shown that administration via
intranasal (IN) and pulmonary routes conferred greater
protection against Mtb and other respiratory infections, at
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MATERIALS AND METHODS
Mouse Model Experimental Matrix
The experimental matrix, shown in Table 1, was designed to
assess the viability of intranasal and pulmonary routes of
administration of the spray-dried version of the ID93+GLA-SE
vaccine. The dosing target was 0.4 µg of ID93 antigen and 1 µg of
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TABLE 1 | Experimental matrix for the assessment of administration route of spray-dried ID93+GLA-SE forms in mice. Nomenclature: V–Vaccine; A–Adjuvant; L–Liquid;
D–Dry powder; N–Nose; NL–Nose and Lung.
Group

Immunization

Presentation

Route

Intended Deposition

Immunogenicity

Protective Efﬁcacy

1

Vaccine

Spray-dried (reconstituted)

Intramuscular

Muscle

Spray-dried (reconstituted)

Intranasal

Nose

Vaccine

Spray-dried (reconstituted)

Intranasal

Nose

4

Adjuvant-only

Spray-dried - large particle

Dry aerosol

Nose

5

Vaccine

Spray-dried - large particle

Dry aerosol

Nose

6

Adjuvant-only

Spray-dried - small particle

Dry aerosol

Nose + Lungs

7

Vaccine

Spray-dried - small particle

Dry aerosol

Nose + Lungs

Lot:
N
Lot:
N
Lot:
N
Lot:
N
Lot:
N
Lot:
N
Lot:
N

Lot:
N
Lot:
N
Lot:
N
Lot:
N
Lot:
N
Lot:
N
Lot:
N

2

Adjuvant-only

3

V-L
16
A-L
16
V-L
16
A-D-N
8 (×2)
V-D-N
8 (×2)
A-D-NL/1
8 (×2)
V-D-NL
8 (×2)

V-L
10
A-L
10
V-L
10
A-D-N
10
V-D-N
10
A-D-NL/2
10
V-D-NL
10

on these ﬁndings, the formulation to assess intranasal delivery
through nose-only deposition was designed to have a da ≈ 5 μm,
and the formulation to assess pulmonary delivery through both nose
and lung deposition was designed to have a da of 1–2 µm.
Assuming as a ﬁrst approximation that the spray-dried particles
have no voids and are spherical, their geometric diameter, dg , can be
estimated using Eq.1, where cF is the solids concentration of the
feedstock, ρt is the true density of the particle, and dD is the diameter
of the atomized droplets. Based on this equation, it is apparent that
the size of particles can be inﬂuenced by modifying the feedstock
concentration or by adjusting the processing conditions to change
the atomized droplet diameter.

cF
(1)
dg  3 dD
ρt

GLA adjuvant delivered to each mouse. The ﬁrst group of mice
was immunized with the reconstituted vaccine via intramuscular
injection as a positive control. The remaining groups assessed
delivery of the reconstituted formulation to the nose [liquid
intranasal administration (Group 3)], delivery of the dry
powder formulation targeting deposition in the nose [dry
powder intranasal administration (Group 5)], and delivery of
the dry powder formulation targeting deposition in the nose and
lungs [dry powder pulmonary administration (Group 7)].
Isolated delivery to the lungs is not possible using a nose-only
exposure system given that mice are obligate nose breathers.
Each of the routes targeting respiratory delivery was also tested
with adjuvant-only formulations that did not contain the antigen
as negative controls (Group 2, 4, 6). Immunogenicity studies and
protective efﬁcacy studies were completed for each experimental
group. Immunogenicity studies were conducted on 16 mice per
group and protective efﬁcacy studies were conducted on 10 mice
per group. The maximum number of mice that could ﬁt within
the aerosol delivery device at a time was 12; therefore, the
immunogenicity studies on the inhaled dry powder Groups 4,
5, 6, and 7 were completed in two sets of 8. The animal
experiments in Table 1 were repeated once, although some of
the speciﬁc immunogenicity readouts were not repeated in order
to accommodate a larger diversity of complementary readouts
between studies.

The true density of the particles can be calculated using Eq.2,
where Yi is the mass fraction of a given component and ρi is the
component’s true density. The density of the spray-dried vaccines
can be approximated using the densities of the excipients
trehalose, 1,580 kg/m3 (Grasmeijer et al., 2016), and trileucine,
1,250 kg/m3 (Carrigy et al., 2020). These values were used to
calculate appropriate spray drying conditions suitable for
manufacturing the powder at the targeted particle sizes.
ρt 

1
i ρYi

(2)

t,i

Formulation Development of Suitable
Inhalable Particles for Mice

Materials and Formulation Composition

Two formulations were designed in order to assess both intranasal
and pulmonary delivery via dry powder inhalation. The
aerodynamic diameter, da , of an aerosol can be used as an
important predictor of deposition site in respiratory systems.
Kuehl et al. (Kuehl et al., 2012) conducted a study on the
deposition of polydisperse aerosols in rodents as a function of
aerosol da . Of the particle sizes investigated in the study, they
found that a minimum da of 5 µm was required for nose-only
deposition for mice (Kuehl et al., 2012). A maximum da of 3 µm was
required to obtain at least some lung deposition for mice, with lung
deposition increasing with decreasing da (Kuehl et al., 2012). Based

The feedstock was prepared similarly to previous studies on spray
drying the ID93+GLA-SE vaccine (Gomez et al., 2021a; Gomez
et al., 2021b; Gomez et al., 2021c). All solutions were prepared
with deionized water. Trehalose dihydrate with a purity of 98%
(CAS 6138-23-4; Fisher Scientiﬁc Ottawa, ON, Canada) was used
as the primary stabilizing agent. Formulations designed for dry
powder delivery included trileucine with a purity of ≥90% (CAS
10329-75-6; Sigma Aldrich, Oakville, ON, Canada) as a
dispersibility enhancing agent. All formulations included a
buffer system
consisting
of Tris
(hydroxymethyl)
aminomethane (Tris) (CAS 77-86-1; Sigma Aldrich, Oakville,
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ON, Canada) and hydrochloric acid (CAS 7647-01-0; Sigma
Aldrich, Oakville, ON, Canada) adjusted to a pH of 7.5.
The ID93 antigen and GLA-SE adjuvant components of the
vaccine were produced separately. The construction, expression,
and puriﬁcation of the ID93 recombinant fusion protein has been
described previously (Bertholet et al., 2010). Brieﬂy, ID93 was
expressed in E. coli, puriﬁed under denaturing conditions by
chromatography, and analyzed by SDS-PAGE. GLA-SE was
formulated with squalene droplets and dimyristoyl-sn-glycero3-phosphocholine (DMPC) as an emulsiﬁer. Manufacture of
GLA-SE generally followed the same procedure as described in
Orr et al. (Orr et al., 2014), except that the oil phase in the present
work included the addition of α-tocopherol (0.05% w/v) and that
glycerol and buffer were omitted from the aqueous phase. Three
different lots of varying GLA concentrations were manufactured
to achieve the target delivered GLA dose. All lots had an initial
emulsion droplet size of 91–107 nm in diameter and low
polydispersity indexes. ID93 protein was stored at a
concentration of 1.2 mg/ml at −80°C prior to use. GLA-SE
nanoemulsions with a squalene concentration of 10% v/v and
GLA concentrations of 50 μg/ml or 5 mg/ml were stored in a
refrigerator prior to use. All formulation processes began with
preparation of 4 mg/ml Tris. The Tris solution was then pH
adjusted by addition of hydrochloric acid to a pH of 7.5 ± 0.1. For
each formulation, the trehalose and trileucine (if added) were
dissolved in water into buffered Tris solution. Once fully
dissolved, GLA-SE was added to the solution and gently
mixed. ID93 was added last to the feedstock to minimize
potential protein binding to container surfaces.
The custom aerosol delivery system was tested for feasibility
and optimized prior to conducting the mouse study. This system
was characterized with two vehicle (vaccine-free) formulations
that were designed to be representative of the formulations used
in the mouse study. The ﬁrst formulation, C1, was designed to
represent the powders intended for deposition in the nose
following aerosolized dry powder delivery. The second
formulation, C2, was designed to represent the powders
intended for deposition in the nose and lungs after dry
powder aerosolization. These representative powders were
designed to have the same feedstock concentration of the
trehalose, trileucine, and Tris components as their murine
study counterparts. The feedstock concentrations and powder
compositions of the vehicle-only spray-dried powders were as
follows: C1 consisted of trehalose, trileucine, and Tris buffer with
feedstock concentrations of 100 mg/ml, 3.3 mg/ml, and 2.4 mg/
ml, respectively. C2 consisted of trehalose, trileucine, and Tris
buffer with feedstock concentrations were 3.3 mg/ml, 0.11 mg/ml,
and 0.08 mg/ml, respectively. The corresponding trehalose,
trileucine, and Tris buffer mass fractions in both powders
were 94.6, 3.1, and 2.3%, respectively. These spray-dried
powders were used to optimize the aerosol delivery system
while eliminating the chance of aerosolized exposure to
ID93+GLA-SE.
The manufactured lots used for each murine study experiment
were listed previously in Table 1. For consistency, one batch of
powder was manufactured per experimental group, including
replicates. However, the V-L and A-D-NL powders had to be
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completed in two batches due to limitations in processing
capability. The V-L powder consisted of two separately
prepared batches (V-L/1, and V-L/2) that were mixed in a 1:1
ratio by mass. This was not done for the A-D-NL/1 and A-D-NL/
2 powders due to inability to guarantee evenly dispersed powders
for aerosolization. This was not a concern for the V-L powder as it
was intended for reconstitution prior to administration.
Characterization of the powders was performed for each batch.
The solution preparation and mass fraction of the resulting
powder for each formulation are given in Table 2 and Table 3,
respectively. The formulations designed for reconstitution prior
to delivery were based on a spray-dried ID93+GLA-SE vaccine
developed in a previous study (Gomez et al., 2021a). Similarly,
formulations designed for dry powder aerosol delivery to the nose
or nose and lungs were modiﬁed from a human inhalable spraydried presentation of ID93+GLA-SE investigated in a previous
study (Gomez et al., 2021c).
Optimization experiments with the C1 and C2 formulations
(see Results) demonstrated that it would not be possible to deliver
the target dose of 0.4 µg of ID93 and 1 µg of GLA through dry
powder inhalation with the same mass fraction of ID93 and GLA
as the powders intended for reconstitution. The main constraint
was the tolerable aerosol concentration and dosing time for the
mice. To achieve the target delivered dose, the ID93 and GLA
concentrations in the dry powder aerosol formulations were
concentrated 100×. However, it was not possible to similarly
concentrate squalene and emulsiﬁer content due to practical
limitations. Therefore, whereas ID93 and GLA dose were
intended to be constant regardless of formulation phase or
route of delivery, squalene dose was ∼100-fold lower in the
dry powder aerosol formulations for nasal or pulmonary
delivery compared to the reconstituted liquid formulations.
Nevertheless, the impact of this limitation was expected to be
minimal since our previous work indicated that squalene was not
necessary for immunogenicity or protective efﬁcacy following
intranasal immunization with ID93 + GLA (Orr et al., 2015).
Finally, previous development work (data not shown) suggested
that manufacturing of the powders for nose and lung delivery
resulted in greater ID93 processing loss due to the harsher
processing conditions needed to achieve the required small
particle size. Therefore, the solution concentration of ID93 in
the V-D-NL formulation was increased further relative to the
other formulations, assuming an approximately 50%
processing loss.

Spray Drying
Spray drying was conducted using similar equipment to that
described in previous studies (Gomez et al., 2021a; Gomez et al.,
2021b; Gomez et al., 2021c). Brieﬂy, the feedstock was supplied to
an atomizer using a peristaltic pump. The feedstock was
subsequently atomized into a custom-built research spray
dryer. The powders were collected into glass jars at the outlet
of the spray dryer. The collected powders were stored in a dry
environment prior to packaging.
The processing parameters used for spray drying the C1 and
C2 formulations for the characterization of the RBG-NOID were
as follows: C1 was processed with a drying gas ﬂow rate of 500
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TABLE 2 | Solution preparation for manufacture of each experimental group composition. Nomenclature: V–Vaccine; A–Adjuvant; L–Liquid; D–Dry powder; N–Nose;
NL–Nose and Lung.
Component

Trehalose
Trileucine
Tris (buffer)
Squalene
DMPC
GLA
ID93

Group 1 and 3

Group 2

Group 4

Group 5

Group 6

Group 7

(V-L)

(A-L)

(A-D-N)

(V-D-N)

(A-D-NL)

(V-D-NL)

100 mg/ml
—
2.4 mg/ml
17.2 mg/ml
3.8 mg/ml
0.01 mg/ml
0.004 mg/ml

100 mg/ml
—
2.4 mg/ml
17.2 mg/ml
3.8 mg/ml
0.01 mg/ml
—

100 mg/ml
3.9 mg/ml
2.4 mg/ml
17.2 mg/ml
3.8 mg/ml
1 mg/ml
—

100 mg/ml
3.9 mg/ml
2.4 mg/ml
17.2 mg/ml
3.8 mg/ml
1 mg/ml
0.4 mg/ml

3.33 mg/ml
0.128 mg/ml
0.081 mg/ml
0.57 mg/ml
0.13 mg/ml
0.033 mg/ml
—

3.33 mg/ml
0.128 mg/ml
0.081 mg/ml
0.57 mg/ml
0.13 mg/ml
0.033 mg/ml
0.027 mg/ml

TABLE 3 | Mass fraction composition of each formulation. Nomenclature: V–Vaccine; A–Adjuvant; L–Liquid; D–Dry powder; N–Nose; NL–Nose and Lung. *Expected ID93
mass fraction for Group 7 calculated from solution preparation assuming ∼50% processing loss.
Component

Trehalose
Trileucine
Tris (buffer)
Squalene
DMPC
GLA
ID93

Group 1 and 3

Group 2

Group 4

Group 5

Group 6

Group 7

(V-L)

(A-L)

(A-D-N)

(V-D-N)

(A-D-NL)

(V-D-NL)

81.0%
—
2.0%
13.9%
3.1%
0.008%
0.003%

81.0%
—
2.0%
13.9%
3.1%
0.008%
—

77.9%
1.9%
3.0%
13.4%
3.0%
0.8%
—

77.9%
1.9%
3.0%
13.4%
3.0%
0.8%
0.3%

77.9%
1.9%
3.0%
13.4%
3.0%
0.8%
—

77.9%
1.9%
3.0%
13.4%
3.0%
0.8%
0.3%*

SLPM, an inlet temperature of 70°C, an atomizing gas pressure of
69 kPa, a liquid feed ﬂow rate of 1.8 ml/min, a predicted outlet
temperature of 46°C, a predicted outlet RH of 6%, and an
atomizer air-liquid ratio of 3; C2 was processed with a drying
gas ﬂow rate of 800 SLPM, an inlet temperature of 70°C, an
atomizing gas pressure of 552 kPa, a liquid feed ﬂow rate of
3.3 ml/min, a predicted outlet temperature of 49°C, a predicted
outlet RH of 8%, and an atomizer air-liquid ratio of 10. These
spray drying conditions were calculated iteratively using an
energy and mass balance model (Ivey and Vehring, 2010) to
maximize or minimize the initial atomized droplet size for the C1
and C2 powders, respectively. A relatively low outlet temperature
and relative humidity was also prioritized to reduce losses at the
collection point. Based on the processing conditions and
feedstock concentration, the theoretical mass median diameter
was 4.6 and 1.1 µm for the C1 and C2 formulations, respectively.
The processing parameters used to spray dry the formulations
for the mouse studies are given in Table 4. The conditions used to
spray dry the formulations designed for reconstitution prior to
delivery (V-L and A-L) were the same as used in a previous study
(Gomez et al., 2021a). The conditions used to spray dry the
powders for dry powder administration to the nose (A-D-N and
V-D-N) were similar to those used to spray dry the C1
formulation. The conditions used to spray dry the powders for
aerosolized dry powder administration to the nose and lungs
(A-D-NL and V-D-NL) were similar to those used to spray dry
the C2 formulation. Both of these conditions were chosen to
maximize or minimize the initial droplet diameter to achieve
larger or smaller particles, respectively. Collected powders were
packaged to minimize moisture exposure in the time between
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manufacture and usage. This packaging method was used
successfully in previous stability studies (Gomez et al., 2021a;
Gomez et al., 2021c). Brieﬂy, powders were aliquoted into
separate low-bind snap cap tubes by mass based on the given
experiment. Powder-containing tubes were individually packaged
in aluminum bags along with a desiccant pouch and heat sealed.
These packages were then placed within another aluminum bag
with a desiccant pouch and heat sealed. The packages were kept
refrigerated prior to use.

Characterization of Aerosol Delivery
System
This study used a nose-only exposure system to dose the mice
with the dry powder, instead of the insufﬂation method that was
often used in the past. Although insufﬂation is efﬁcient, this
method does not allow for realistic aerosol particle sizes and
deposition patterns and is thus not representative of inhalation in
humans. A rotating brush generator (RBG) system (RBG 1000G;
Palas GmbH, Karlsruhe, Germany) was utilized to disperse the
spray-dried powder into an aerosol. The conﬁguration used for
this study included a 7 mm diameter feedstock reservoir and
dispersion cover type C. The RBG device was connected to a
modiﬁed version of a custom-made nose-only inhalation device
(NOID), ﬁrst developed by Nadithe et al. (Nadithe et al., 2003).
The modiﬁed version of the NOID has been used before in
immunogenicity and protective efﬁcacy mouse studies with
nebulized bacteriophage (Carrigy et al., 2019). A simpliﬁed
schematic of the RBG and NOID system (RBG-NOID) with
an exit ﬁlter is shown in Figure 1 (top).
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TABLE 4 | Spray drying processing parameters used for manufacturing powder for preclinical trials. Nomenclature: V–Vaccine; A–Adjuvant; L–Liquid; D–Dry powder;
N–Nose; NL–Nose and Lung.
Parameters

Drying Gas Flow Rate (SLPM)
Inlet Temperature (°C)
Atomizing Gas Pressure (kPa)
Liquid Feed Flow Rate (ml/min)
Predicted Outlet Temperature (°C)
Predicted Outlet RH (%)

Group 1/2/3
(V-L and A-L)

Group 4/5
(A-D-N and V-D-N)

Group 6/7
(A-D-NL and V-D-NL)

200
65
69
0.6
36
7

400
70
69
1.8
43
8

750
75
552
3.3
50
8

The spray-dried powder and aerosol delivery system was
designed for preclinical trials involving C56BL/6 mice. The
approximate average respiratory minute volume, Vm , was
calculated to be 22 ml/min per mouse for the same strain of
mice (Carrigy et al., 2019). This value is similar to the generally
given Vm for laboratory mice (23 ml/min) (Cryan et al., 2007).
The maximum respiratory minute volume is 264 ml/min given
that the maximum number of mice that can be housed in the
NOID is 12. Including a safety factor of 2, the minimum aerosol
ﬂow rate to prevent a hypoxic environment for the mice is
528 ml/min. All experiments were conducted at the lowest
possible system air ﬂow rate, 0.5 m3/h (8.33 L/min). The
lowest ﬂow rate was chosen to minimize the difference
between the mouse inhalation rate and the aerosol ﬂow rate
and thus increase the aerosol available to the mice. All
experiments were conducted at the maximum brush-rotating
speed, 1,200 rpm, to maximize the dispersing force.
Powder was loaded into the RBG reservoir within a dry
environment in order to minimize moisture uptake. The mass
of the powder loaded into the reservoir (nominal dose) was
recorded as the difference in the powder stock container mass
before and after loading powder. Mouse noseports were
plugged for the characterization experiments. Experiments
consisted of aerosolizing the C1 or C2 powder using the RBG
and determining the delivery efﬁciency through the NOID.
Two piston feed rates were assessed: ∼300 mm/h and
150 mm/h. Repeat experiments at ∼300 mm/h were
conducted to assess repeatability of the results. An exit
ﬁlter (VP7100; KEGO Corporation, London, ON, Canada)
was placed at the outlet of the NOID and was measured
gravimetrically before and after each experiment to
determine powder deposition on the exit ﬁlter. Airﬂow was
run for an additional minute after all powder was aerosolized
by the RBG in order to allow any remaining aerosol to
traverse the system. The equipment was completely
cleaned and dried between each experiment.
Lower piston feed rates were not investigated due to a selected
duration of exposure limit of 20 minutes. Mice have been
reported to tolerate restraint tubes for less than an hour, even
after acclimation to the devices (Phillips et al., 2017). Retention of
the mice in the tubes for longer periods of time may lead to stressinduced breathing pattern changes. Additionally, a maximum of
3 mg/L of aerosol concentration at the noseports was set to limit
mouse distress due to high aerosol concentration. The aerosol
concentration at the noseports, Cn , can be calculated using Eq.3,

FIGURE 1 | (A): Schematic of the aerosol delivery system, consisting of
the RBG system (Phillips et al., 2017) connected to the NOID. Spray-dried
powder is loaded into the RBG system, which then aerosolizes the powder. The
powder aerosol traverses the NOID to be inhaled through the nose of the
mice. Red arrows represent the ﬂow of clean air, and green arrows represent the
ﬂow of aerosolized powder. (B): Simpliﬁed schematic of the system used to
assess aerosol particle size at the outlet of the aerosol delivery system. Aerosol
particle size at the outlet of the RBG-NOID was measured using an aerodynamic
particle sizer (APS). Abbreviations and nomenclature: RBG–Rotating Brush
Generator, NOID–Nose-Only Inhalation Device, APS–Aerodynamic Particle
Sizer, Qo–ﬂow rate at the outlet of the RBG-NOID apparatus (8.33 L/min),
Qs–sampling ﬂow rate of the APS (5 L/min), Qf–ﬂow rate of the air exiting the ﬁlter
from the tee ﬁtting. Figures created with BioRender.com.
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Carl Zeiss, Oberkochen, Germany). Powder was mounted onto a
carbon tape-covered aluminum SEM stub (Product 16,111; Ted
Pella, Inc.; Redding, CA, United States), and subsequently
samples were sputtered with a gold coating (Denton Vacuum
Desk II Sputter Coater; Denton, Moorestown, NJ, United States)
to a thickness of approximately 16 nm. Images were taken at a
magniﬁcation of 3,000–5,000x.

where mn refers to the mass of spray-dried powder delivered to
the noseports and D is the duration of exposure.
mn
Cn 
(3)
Vm × D
The mass of powder that deposited on the exit ﬁlter was used
to estimate the amount of powder that was delivered to each of
the noseports using a ratio of ﬂow rates, as given in Eq.4. In this
equation, mf refers to the measured mass of powder deposited on
the exit ﬁlter, and Qo is the aerosol ﬂow rate at the outlet of the
RBG-NOID device (8.33 L/min). The delivered dose is deﬁned as
the dose available for breathing, as compared to the deposited
dose, which is deﬁned as the dose that deposits in the lung. This
distinction was made explicit as the deposited dose is expected to
be much lower than the delivered dose, with the FDA estimating
that only 10% of aerosol delivered to rodents will reach the
respiratory system (Tepper et al., 2016).
mn Vm

mf Qo

Dynamic Light Scattering
For each formulation, the size of the GLA-SE nanoemulusion
droplets was assessed after reconstituting the spray-dried
formulation back to the feedstock concentration. Mean
hydrodynamic diameter and polydispersity of the
nanoemulsion droplets were measured using dynamic light
scattering with a measurement angle of 173° (NanoZS;
Malvern, Worcestershire, United Kingdom). The mean
hydrodynamic diameter and polydispersity index were
calculated by the instrument software from a cumulants
analysis of the intensity autocorrelation function.

(4)

Following the optimization characterization experiments, a
feed rate of 150 mm/h was chosen to assess the dispersing
capabilities of both the spray-dried C1 and C2 formulations.
The particle size distribution at the outlet of the aerosol delivery
system was measured to determine if the tested powder was
adequately dispersed. A ﬂexible hose was connected at one end to
the outlet of the NOID and connected at the other end to an
aerosol diluter (Aerosol Diluter 3302A; TSI, Shoreview, MN,
United States) mounted on a time-of-ﬂight aerodynamic
particle sizer (APS) (Aerodynamic Particle Sizer Spectrometer
3,321; TSI, Shoreview, MN, United States). The aerosol ﬂow rate
of the RBG-NOID at operation was 8.33 L/min and the sampling
ﬂow rate of the APS was 5 L/min. To prevent pressure buildup
within the system, a tee ﬁtting with a ﬁlter (VP7100; KEGO
Corporation, London, ON, Canada) was attached to the hose
prior to the diluter and APS system. A simpliﬁed schematic of this
sampling setup is shown in Figure 1. Clear, ﬂexible tubing was
used to transfer the aerosol from the outlet of the RBG-NOID to
the sampling system. Flexible tubing was used to avoid sharp
changes in ﬂow direction as gently curved streamlines will
mitigate large particle deposition as compared to abrupt
changes during aerosol transportation through the tubing.
The APS device measures the count median aerodynamic
diameter, CMAD, and the geometric standard deviation, σ g . The
mass median aerodynamic diameter, MMAD, was calculated using
the Hatch-Choate equation, as shown in Eq.5. Six and nine
recordings were obtained for the C1 and C2 formulations,
respectively.
MMAD  CMAD · e3 ln (σ g )
2

Reverse-phase HPLC
Squalene and GLA content for each formulation were quantiﬁed
after reconstitution by reversed phase HPLC using an Agilent
1200 HPLC (Agilent Technologies; Santa Clara, CA,
United States) equipped with a silica-based, C18 reversedphase column (Atlantis T3 Column; Waters; Elstree,
United Kingdom) held constant at 30°C. Each analyte was
detected using a charged aerosol detector (Corona CAD; ESA
Biosciences; Chelmsford, MA, United States). Mobile phase A
contained 75:15:10 (v/v/v) methanol:chloroform:water, 1% (v/v)
acetic acid, and 20 mM ammonium acetate, and mobile phase B
contained 50:50 (v/v) methanol:chloroform, 1% (v/v) acetic acid,
and 20 mM ammonium acetate. Samples were diluted in mobile
phase B and injected with a gradient over 30 min for squalene
content analysis or 18 min for GLA content analysis. Squalene
content was quantiﬁed by peak area and GLA content was
quantiﬁed by peak height. Concentration measurements were
made by interpolation from a curve generated from standards
ﬁtted with a second order polynomial. Samples were diluted in
mobile phase B at different factors depending on the expected
GLA and squalene content. Groups 1–3 were diluted 1:10 for
GLA and 1:100 for squalene. Groups 4-5 were diluted 1:1,250 (1:5
and 1:10 with water, 1:25 with mobile phase B in serial) for GLA
and 1:100 for squalene. Groups 6–7 were diluted 1:25 for GLA
and 1:10 for squalene.
SDS-PAGE
ID93 concentration was quantiﬁed after reconstitution back to
the feedstock concentration using densitometry analysis of
reducing SDS-PAGE based on a standard curve. Samples were
prepared by mixing a 20% (w/v) sodium dodecyl sulfate solution
(Thermo Fisher Scientiﬁc, Waltham MA, United States), 4X LDS
Buffer (Thermo Fisher Scientiﬁc, Waltham, MA, United States)
spiked with 5% (v/v) β-mercaptoethanol, and reconstituted
sample in a 2:1:1 ratio. Due to the elevated ID93
concentration, prepared Group 5 (V-D-N) samples were
diluted 1:50 to bring ID93 concentration into the range of the

(5)

Characterization of Spray-Dried
Formulations
Scanning Electron Microscopy
Assessment of particle morphology was completed using Field
Emission Scanning Electron Microscopy (Zeiss Sigma FE-SEM;

Frontiers in Pharmacology | www.frontiersin.org

7

January 2022 | Volume 12 | Article 799034

Gomez et al.

Spray-Dried Tuberculosis Vaccine Candidate

standard curve. The upper limit of quantitation of the assay is
0.02 mg/ml ID93. Samples were heated for 15 min at 85°C and
loaded into a 4–20% Tris-Glycine SDS-PAGE gel (Thermo Fisher
Scientiﬁc, Waltham, MA, United States). The gel was run at 180V
for 65 min and then stained overnight using a SYPRO Ruby stain
(Thermo Fisher Scientiﬁc, Waltham, MA, United States) and
imaged (ChemiDoc; Bio-Rad, Mississauga, ON, Canada).
ID93+GLA-SE standards at 10 ng, 50 ng, and 100 ng protein
load were prepared in the same manner and included on each
gel. Densitometry analysis was performed using Image Lab 6.0
software (Bio-Rad Laboratories, Hercules, CA, United States).
The three standards were used to generate a standard curve based
on band intensity and ID93 was interpolated from the
standard curve.

the immunogenicity studies, 5 mice (out of 224 total mice) died
24–48 h following immunizations (1 mouse administered liquid
nasal GLA-SE, 1 mouse administered nasal aerosol GLA-SE, and
3 mice administered nasal aerosol ID93+GLA-SE). In the
protective efﬁcacy studies, 5 mice (out of 140 total mice) died
following immunizations (1 mouse administered liquid nasal
GLA-SE, 1 mouse administered nasal aerosol ID93+GLA-SE, 2
mice administered pulmonary aerosol GLA-SE, and 1 mouse
administered pulmonary aerosol ID93+GLA-SE). In the
protective efﬁcacy studies, mice were challenged 4 weeks after
the second immunization by aerosol with a low dose [100 colony
forming units (CFU)] of Mtb strain H37Rv (BEI Resources,
Manassas, VA, United States) using a Glas-Col airborne
infection system (Glas-Col LLC, Terre Haute, IN,
United States). Four weeks after challenge, unvaccinated and
vaccinated mice were sacriﬁced by carbon dioxide (CO2)
asphyxiation, and the lungs were aseptically excised and
individually homogenized in physiological saline solution.
Serial dilutions of lung and spleen homogenates were plated
on 7H11 selective agar (BD bioscience, San Diego, CA,
United States) for Mtb CFU and counted after 3 weeks of
incubation at 37°C as described before (Nakae et al., 2002).
For the immunogenicity experiments, lung and spleen singlecell suspensions from immunized, unchallenged mice were
isolated after the second immunization as previously described
(Ardain et al., 2019). Brieﬂy, mice were euthanized with CO2 and
lungs were perfused with heparin in saline. Harvested lungs were
minced and incubated in collagenase/DNAse for 30 min at 37°C.
Lung and spleen tissues were pushed through 70 µm nylon
screens to obtain single-cell suspension. Red blood cells were
lysed with Gey’s Balanced Salt Solution (Sigma-Aldrich, St. Louis,
MO, United States), and the cells were resuspended in complete
DMEM (DMEM+10% FBS) for downstream analysis such as ﬂow
cytometry and ELISA assays. Bronchoalveolar lavage (BAL) was
isolated from immunized animals as previously described (Gopal
et al., 2013; Slight et al., 2013). Brieﬂy, the chest cavity was opened
and the sternum/ribcage was resected. The trachea was isolated
and a blunt tipped needle was gently inserted into the trachea.
The lungs were lavaged with 1 (1 × 1 ml) wash with sterile 0.2 mM
EDTA (Sigma-Aldrich, St. Louis, MO, United States) in PBS.
Bone marrow was harvested and processed as previously
described (Grifﬁths et al., 2016a) at 1 week and 4 weeks after
the second immunization. Brieﬂy, cells were isolated from the
femur and tibia of the immunized animals. Red blood cells were
lysed with Gey’s Balanced Salt Solution, and the cells were
resuspended in cDMEM for ELISpot and antibody ELISA assay.

Mice, Immunizations, Aerosol Challenge,
and Sample Collection
C57BL/6J (B6) (Jackson Laboratories, Bar Harbor, ME,
United States) mice were bred under speciﬁc pathogen-free
conditions at the Infectious Disease Research Institute (IDRI)
(for the initial experiment shown in Supplementary Figure S1)
or at the Washington University in St. Louis (for all other animal
studies). Mice were used at 6–8 weeks of age. All animal
experiments were performed in accordance with National and
Institutional guidelines for animal care of laboratory animals and
approved by the Washington University in St Louis Institutional
Animal Care and Use Committee (IACUC) under protocol
20190101 or by the IDRI IACUC under protocol 2019-6.
For the initial study (Supplementary Figure S1), lyophilized
or spray-dried batches of ID93-GLA-SE were reconstituted prior
to immunization. Cohorts of 5 female mice per group were
immunized once via intramuscular injection in the calf
muscles of hind limbs with 100 μl (50 µl/leg) of either the
vehicle only (10% trehalose + 20 mM Tris pH 7.5 in water) or
0.4 μg of ID93 and 1 μg of GLA in a 2% stable squalene oil
emulsion (SE). Spleens and draining inguinal lymph nodes were
collected in RPMI 7 days post immunization. Cell suspensions
were obtained by manual disruption. Red blood cells contained in
spleens were lysed using the Red Blood Cell Lysis Buffer
(eBioscience, San Diego, CA, United States). Central blood was
collected by cardiac puncture from mice under deep anesthesia
on day 7. Serum was separated from whole blood by
centrifugation at 10,000 rpm for 5 min and was stored at -70°C
until use.
For all subsequent studies, equal numbers of male and female
mice were immunized with ID93+GLA-SE or only GLA-SE
through intramuscular (IM) liquid injection, intranasal (IN)
liquid delivery, or dry powder aerosol delivery to the nose or
nose and lungs, as described in Table 1, at day 0 and at day 21.
Mice were anesthetized using ketamine (80 mg/kg) (AKorn
Animal Health Inc., Lake Forest, IL, United States) and
xylazine (6 mg/kg) (AKorn Animal Health Inc., Lake Forest,
IL, United States) to restrain the mice inside the NOID device
for the aerosol-inhalation immunizations. Whereas for IN
immunizations, mice were anesthetized using isoﬂurane
(Henry Schein Animal Health, Dublin, OH, United States). In
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Flow Cytometry Staining
In
the
initial
mouse
immunogenicity
experiment
(Supplementary Figure S1), cells were incubated with the
I-A(b) Mtb Rv3619 63–73 VIYEQANAHGQ tetramer (NIH
Tetramer Core Facility at Emory University, Atlanta, GA,
United States) and Fc receptor block (anti-CD16/32 antibody,
eBioscience) for 1 h at 37°C. Cells were then surface stained with
CXCR5, CD8, B220, CD11b, PD-1, CD4, and CD44. Cells were
subsequently permeabilized in Foxp3/Transcription factor Fix
and Perm buffer (eBioscience) for 1 h at RT and then stained
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overnight at 4°C with FoxP3 and T-bet. Cells were gated as
singlets > lymphocytes > CD4+ CD8− B220- CD11b- >
Tetramer + CD44+ > CXCR5+ PD-1+ (TFH) or CXCR5PD1- FoxP3- T-bet+ (TH1) or CXCR5- PD1- FoxP3 (Treg). A
second panel for intracellular cytokine staining was performed
where cells were stimulated for 2 h with media (RPMI 1640 + 10%
FCS) or ID93 (10 μg/ml) at 37°C and subsequently incubated with
Brefeldin A (eBioscience) for an additional 8 h at 37°C. Cells were
surface stained with CD4, CD8, B220, CD11b, and CD44 together
with Fc receptor block, followed by permeabilization with
Cytoﬁx/Cytoperm (BD Biosciences) and intracellular staining
with CD154, TNF, IL-2, GM-CSF, IL-17A, IL-5, and IFN-γ.
Cells were gated as singlets > lymphocytes > CD4+ CD8−
B220- CD11b- > CD44+ > cytokine+. The complete antibody
panels, including ﬂuorochrome, dilution factor, and
manufacturer are listed in Supplementary Table S1, and
representative gating strategies are represented in
Supplementary Figure S2.
In the subsequent mouse immunogenicity experiment, the
antibodies CD154, TNF, CD44, IL-5, IFN-γ, GMCSF, CD8,
IL-17A, CD4, and IL-2 were employed. The complete
antibody panels, including ﬂuorochrome, dilution factor,
and manufacturer are listed in Supplementary Table S1.
Cells were stimulated with ID93 protein (10 μg/ml), along
with Brefeldin A (BioLegend). Following the antigen
stimulation, the cells were stained in 96-well U-bottom
plates using the LIVE/DEAD Fixable yellow Dead Cell
Stain Kit (Thermo Fisher Scientiﬁc, Waltham, MA,
United States) as per the manufacturer’s protocol. The cells
were then stained for surface markers for 30 min. Intracellular
cytokine staining was performed using the BD Cytoﬁx/
Cytoperm kit (BD Biosciences, San Diego, CA) following
manufacturer’s instructions. Intracellular staining with
anti-IFN-γ, IL-2, TNF-α, IL-5, GMCSF, CD154, and IL-17
was performed for 30 min. Cells single stained with each
ﬂuorochrome were used as controls for the compensation
matrix in the ﬂow cytometry (Ardain et al., 2019). Samples
were acquired on a 4 laser BD LSRII or X20 Flow Cytometer,
and the analysis was performed using FlowJo software version
7.6.5 (Treestar, FlowJo, LLC, Ashland, OR, United States).
The gating strategy is represented in Supplementary
Figure S2.

Antigen-speciﬁc Long-Lived Antibody-Secreting
Plasma Cell Responses–B Cell ELISpot Assay
ELISpot plates (Millipore, Bedford, MA, United States) were
coated with 2 μg/ml ID93 and incubated overnight at 4°C.
Plates were washed with PBS, blocked with complete RPMI
and 10% FBS for 2 h, at room temperature, and then washed
again. Single-cell suspensions from harvested bone marrow were
prepared as described above and seeded at 1.5×106 cells per well.
The plates were then incubated at 37°C with 5% CO2 for 3 h,
washed, and HRP-conjugated anti-mouse IgG (H + L) or IgA
antibodies (Southern Biotech, Birmingham, AL, United States)
were added for overnight incubation at 4°C. The plates were
developed with AEC substrate kits according to the
manufacturer’s protocol (Vector Laboratories, Burlingame, CA,
United States). Spots were counted using an automated ELISPOT
reader (CTL. Analyzer, Cellular Technology Ltd., Shaker Heights,
OH, United States). Data were analyzed using ImmunoSpot
software (CTL Analyzer).

Cytokine and Antibody Quantiﬁcation Using
Enzyme-Linked Immunosorbent Assay
For the initial mouse immunogenicity experiment, Corning
high bind 384-well microtiter plates (VWR International,
Radnor, PA, United States) were coated overnight at 4°C
with 2 μg/ml ID93 in coating buffer (eBioscience). Plates
were blocked for 2 h with 1% BSA-PBS, and 12-point 2-fold
serial dilutions of the serum samples were carried out. Detection
antibodies included anti-mouse IgG1, IgG2c, or total IgG
conjugated to horse radish peroxidase (Southern Biotech,
Birmingham, AL, United States). Plates were incubated with
3,3′,5,5′-Tetramethylbenzidine (TMB) for 5 min, and the
reaction was stopped using 1 N H2SO4. Optical density
(O.D.) readings were taken at 450 nm using an automated

Statistical Analysis
For in vivo efﬁcacy and immunogenicity experiments, the
differences between selected groups were analyzed using oneway or two-way ANOVA with appropriate correction for
multiple comparisons as indicated using GraphPad Prism 9.2
(GraphPad Software; San Diego, CA, United States). In cases
where standard deviations were signiﬁcantly different according
to the Brown-Forsythe test, Welch’s ANOVA test was employed
with Dunnet’s T3 correction for multiple comparisons. The
Kruskal-Wallis non-parametric test with Dunn’s correction for
multiple comparisons was used when multiple comparisons were
not possible with Welch’s ANOVA due to limitations of the latter
test when one experimental group has constant values. A p-value
of <0.05 was considered statistically signiﬁcant.

plate reader (ELx808 or Synergy 2, BioTek, Winooski, VT,
United States).
For the subsequent mouse immunogenicity experiments,
splenocytes (2 × 105 cells/well) from immunized animals were
stimulated with 2 μg/ml ID93 for 48 h. IL-17, IFN-γ and IL-5
were quantiﬁed in the supernatant by ELISA, according to
manufacturer’s instructions (R and D Systems, Minneapolis,
MN, United States). Total IgG, IgG1, IgG2a, and IgG2c were
measured in the serum and BAL samples from the immunized
animals using the reagents indicated below from Southern
Biotech. Brieﬂy, the 96-well plates were coated with 2 μg/ml
ID93 antigen overnight at 4°C. The next day, plates were
washed and blocked with 1% BSA. After washing, plates were
incubated with the sera or BAL samples (diluted 5-fold and
serially diluted up to 5 dilutions) followed by incubation at
room temperature for 2 h with the HRP-conjugated antibodies
against total IgG (Cat # 1,031-05), IgG1 (Cat # 1,070-05), IgG2a
(Cat # 1,080-05) and IgG2c (Cat # 1,079-05), and TMB substrate
(VWR, Radnor, PA, United States). The dilution for total IgG was
1:4,000, and for all other antibodies the dilution was 1:2000. The
reaction was stopped using 1N H2SO4, and the data were collected
within 30 min using a plate reader (ELx405 BioTek, Winooski,
VT, United States).
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FIGURE 2 | SEM images of the trileucine-containing C1 (A) and C2 (B) spray-dried powders. These vehicle powders were designed to not have the antigen or
adjuvant system but still be representative of the spray-dried powders developed for the mouse study dry powder administration routes.

TABLE 5 | Summary of RBG-NOID characterization experiments with the spray-dried C1 formulation. The C1 formulation was designed for deposition in the nose of mice
upon inhalation. Abbreviations: RBG–rotating brush generator; NOID–nose only inhalation device.
Test ID

Piston Feed
Rate (mm/hr)

1
2
3

Measured Values

Calculated Values

Nominal Dose
(mg)

D (min)

mf (% nominal
dose)

mn (% nominal
dose)

mn (mg)

Cn (mg/L)

690.1
711.0
495.9

6.7
7.3
11.4

3.29
6.10
8.93

0.009
0.016
0.024

0.06
0.12
0.12

0.41
0.71
0.47

303
304
150

RESULTS

A summary of the parameter optimization experiments for the
spray-dried C2 formulation representing deposition in the nose
and lungs of mice is given in Table 6. Tests 4, 5, and 6 were
completed at approximately the same feed rate in order to assess
the dosing reproducibility. For these tests, a delivered dose of
0.081 ± 0.009% nominal dose was achieved, indicating a similar
level of reproducibility as the C1 formulation. These results
showed that the C2 formulation had a higher delivery
efﬁciency than the C1 formulation under the same operating
conditions.
The aerosol concentration at the noseports for experiments
conducted at ∼300 mm/h feed rate was 3.76 ± 0.97 mg/L, above
the set aerosol concentration limit. Reducing the feed rate
increased the delivery efﬁciency and decreased the aerosol
concentration at the noseports to tolerable levels. Based on
these results, a feed rate of 150 mm/h or lower was
recommended for maximizing the delivery efﬁciency while
ensuring tolerable aerosol concentration at the noseports.
Based on the 0.003 and 0.008% mass fraction of ID93 and
GLA, respectively, in the spray-dried powders developed for
humans (Gomez et al., 2021a; Gomez et al., 2021c),
approximately 13 mg of powder must be delivered to each
mouse. The optimization experiments indicate that this
powder dose could not be achieved under the tested
conditions for either the C1 or C2 formulation. As explained
previously, these experiments led to the decision to concentrate
the ID93 and GLA components for the mouse study by 100× in
the formulations produced for dry powder aerosol delivery to
achieve the dosing target with a reduced amount of powder.

Optimization of Aerosol Delivery System
and Formulation for Nasal and Pulmonary
Delivery
Particle morphology of the antigen-free trileucine-containing C1
and C2 formulations is shown in Figure 2. Both formulations
showed rugose particle morphologies due to the inclusion of
trileucine as a dispersibility enhancer. A rougher surface
morphology enhances powder dispersibility and thus improves
aerosol performance (Gomez et al., 2021b). The C1 formulation
was signiﬁcantly larger in particle size than the C2 formulation, as
designed. Visually, both appeared to be close in size to their
targeted value.
A summary of the optimization experiments for the spraydried C1 formulation representing deposition in the nose of
mice is given in Table 5. Tests 1 and 2 were completed at
approximately the same feed rate in order to assess the dosing
reproducibility; the delivered dose for these tests was 0.013 ±
0.005% nominal dose. Test 3 was completed at a lower feed
piston rate and consequently demonstrated a higher efﬁciency
of powder delivery compared to Test 1 and 2. All tests showed
that the aerosol concentration at the noseports was less than
3 mg/L, and the duration of exposure was less than the 20 min
limit. Based on these experiments, a feed rate of 150 mm/h or
lower was recommended for maximizing the efﬁciency of
dispersing the spray-dried vaccine powder targeting nasal
deposition.
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TABLE 6 | Summary of RBG-NOID characterization experiments with the spray-dried C2 formulation. The C2 formulation was designed for deposition in the nose and lungs
of mice upon inhalation. Abbreviations: RBG–rotating brush generator; NOID–nose only inhalation device.
Test ID

4
5
6
7

Piston Feed
Rate (mm/hr)

Measured Values

Calculated Values

Nominal Dose
(mg)

D (min)

mf (% nominal
dose)

mn (% nominal
dose)

mn (mg)

Cn (mg/L)

852.1
754.1
754.7
637.2

8.0
9.2
6.6
13.7

33.4
27.0
32.0
40.0

0.088
0.071
0.084
0.11

0.75
0.54
0.64
0.67

4.25
2.65
4.39
2.23

306
306
304
150

measured at the outlet of the system was within the 1–2 µm target
for the C2 formulation.

TABLE 7 | Measured particle size distribution of the dispersed C1 and C2
powders at the outlet of the RBG-NOID. Dispersion experiments were
conducted at the optimized feed rate of 150 mm/h. Results shown are the
average ± standard deviation of six measurements for the C1 formulation and nine
measurements for the C2 formulation.
Formulation

C1
C2

APS Measurement
CMAD (µm)

σg

1.9 ± 0.1
1.1 ± 0.1

1.7 ± 0.1
1.5 ± 0.1

Powder Properties Post-processing
Particle morphology of the different lots manufactured for the
mouse study are shown in Figure 3. Morphology for the different
formulations was consistent with previous work spray drying the
ID93+GLA-SE vaccine (Gomez et al., 2021a; Gomez et al., 2021b;
Gomez et al., 2021c). Lots manufactured for IM or IN
reconstituted liquid administration did not include trileucine
as a dispersibility enhancer (A-L, V-L/1, and V-L/2) and
consisted of round particles with overall smooth or lightly
dimpled surfaces. Lots manufactured for dry powder aerosol
delivery (A-D-N, V-D-N, A-D-NL/1, A-D-NL/2, and V-D-NL)
have a more rugose outer particle surface. Of the lots designed for
dry powder aerosol delivery, there is also a difference in size based
on intended site of deposition. Lots designed for deposition in the
nose and lungs (A-D-NL/1, A-D-NL/2, and V-D-NL) have a
signiﬁcantly smaller particle size than the lots designed for
deposition in the nose (A-D-N and V-D-N). The former were
designed to have a much lower overall solids content in the
feedstock, leading to a smaller particle size.
Physicochemical properties of the spray-dried powder were
assessed in terms of nanoemulsion droplet diameter,
polydispersity index, squalene content, GLA content, and ID93
content. Due to the nature of these assays, it was necessary to
reconstitute the spray-dried powders prior to analysis even for the
formulations intended for dry powder delivery. Comparison of the
adjuvant properties of the spray-dried powder to the feedstock liquid
is shown in Figure 4. Target range was deﬁned as nanoemulsion
droplet diameter of 120 ± 40 nm, size polydispersity index <0.2, and
squalene and GLA content ±20% of the target solution concentration
(Table 3). Target range was based on acceptance criteria used in
previous studies (Gomez et al., 2021a; Gomez et al., 2021c). The
measured nanoemulsion droplet diameter, squalene content, and
GLA content were within the target range for all spray-dried lots.
The size polydispersity index of the V-D-N and V-D-NL lots was
above the target range; however, this result may not be meaningful in
practice since these two batches were intended for delivery as dry
powders rather than reconstituted emulsion droplets.
The ID93 concentrations of the liquid feedstock and the
reconstituted spray-dried powder of the vaccine-containing lots
are given in Table 8. The spray-dried lots V-L/1 and V-L/2,
which were intended for delivery upon reconstitution, were above
and below the target ID93 concentration, respectively. These lots

Calculated MMAD (µm)

4.4 ± 0.4
1.7 ± 0.2

However, it was not possible to similarly concentrate squalene
and emulsiﬁer content due to practical limitations. Therefore,
squalene dose was ∼100-fold lower in the dry powder aerosol
formulations for nose or nose and lung delivery compared to the
reconstituted liquid formulations. However, previous work
indicated that squalene was not necessary for protective
efﬁcacy following IN immunization with ID93 + GLA (Orr
et al., 2015).
The C1 and C2 powders were aerosolized using the RBGNOID system and sized to assess how well the aerosol system was
dispersing the powders. The results of the size distribution
measurements are shown in Table 7. As previously discussed,
the da targets were ∼5 μm and 1–2 µm for the formulations
targeting nose-only deposition, and nose and lung deposition
in mice, respectively.
A gently curved hose was used to connect the RBG-NOID
outlet to the APS system in order to minimize deposition of large
particles during transfer thereby shifting the measured size
distribution to the lower size. For experiments on the C1
formulation, some deposition was seen within the tubing,
indicating that despite precautions there was some particle
deposition of the aerosol prior to reaching the APS system.
Regardless, the MMAD of 4.4 ± 0.4 µm as measured at the
outlet of the system demonstrated that the C1 formulation
was close to target.
The APS device measures the particle size distribution of an
aerosol by separating the particle measurements into bins before
ﬁtting the data to a lognormal distribution in order to calculate
CMAD and σg. The size range of the APS was 0.5–20 μm, with the
lowest bin measuring all particles with aerodynamic particles
<0.523 µm. Therefore, the CMAD reported by the APS system for
the nose and lung C2 formulation may be higher than the actual
CMAD of the powder. Regardless, the MMAD of 1.7 ± 0.2 µm as
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FIGURE 3 | SEM images of the spray-dried powders prepared for the mouse model experiments. The lots containing trileucine that were designed for delivery of
dry powder (A-D-N, V-D-N, A-D-NL/1, A-D-NL/2, and V-D-NL) demonstrate a more rugose particle morphology as compared to the lots intended for delivery after
reconstitution (A-L, V-L/1, and V-L/2). The lots designed for dry powder deposition in the nose (A-D-N and V-D-N) are signiﬁcantly larger than the lots designed for dry
powder deposition in the nose and lungs (A-D-NL/1, A-D-NL/2, and V-D-NL). Smaller particles were designed to promote greater airway penetration. Scale bars
are based on the respective images. Nomenclature: V–Vaccine; A–Adjuvant; L–Liquid; D–Dry powder; N–Nose; NL–Nose and Lung.

Intramuscular Immunization With
Reconstituted Spray-Dried ID93+GLA-SE
Provides Similar Immunogenicity Proﬁle
as Reconstituted Lyophilized
ID93+GLA-SE

were mixed in a 1:1 ratio by mass to generate a single V-L lot for
delivery with a calculated concentration of 0.0044 mg/ml, which was
within the target range. All other measured vaccine properties were
within the target concentration for both lots. The ID93
concentration of the spray-dried V-D-N lot was within target
range. The ID93 concentration of the V-D-NL lot was just above
target concentration; however, due to timeline and material
constraints, this lot was deemed acceptable for the study.
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To evaluate whether reconstituted spray-dried powder
ID93+GLA-SE
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et
al.,
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FIGURE 4 | Comparison of the physicochemical properties before and after spray drying of the lots manufactured for the mouse model in terms of (A)
nanoemulsion droplet diameter, (B) polydispersity index, (C,D) squalene content, and (E–G) GLA content. Measurements of the feedstock liquid are given in black,
whereas measurements of the reconstituted powder are given in grey, for each lot. Results are reported as the mean ± standard deviation. The target range for each
lot is demonstrated by the red dashed lines. Target range was a nanoemulsion droplet diameter measured as 120 ± 40 nm, polydispersity index <0.2, and
squalene and GLA content ±20% of the target feedstock concentration. Nomenclature: V–Vaccine; A–Adjuvant; L–Liquid; D–Dry powder; N–Nose; NL–Nose and
Lung.

TABLE 8 | Comparison of the ID93 concentration of the liquid feedstock and the spray-dried powder as compared to the target concentration. Results are reported as the
mean ± standard deviation. Nomenclature: V–Vaccine; L–Liquid; D–Dry powder; N–Nose; NL–Nose and Lung, ULOQ–Upper Limit of Quantitation (see Methods
section).
Formulation

V-L/1
V-L/2
V-D-N
V-D-NL

Target Range ID93
Concentration (mg/ml)

Liquid Feedstock ID93
Concentration (mg/ml)

Reconstituted Powder ID93
Concentration (mg/ml)

0.0032–0.0048
0.0032–0.0048
0.32–0.48
0.010–0.016

0.0059 ± 0.0012
0.005
0.57 ± 0.017
ULOQ

0.0064 ± 0.0004
0.0023 ± 0.0001
0.41 ± 0.008
0.017 ± 0.0007

immunogenicity performance compared to the reconstituted
lyophilized ID93+GLA-SE developed previously (Kramer
et al., 2018), C57Bl/6 WT mice (n  5/group) were IM
immunized once with either formulation or with an
excipient placebo containing trehalose in Tris buffer. One
week following immunization, enumeration of tetramerstained CD4+ T cells, cytokine production from
intracellularly-stained CD4+ T cells, and serum antibody
titers were measured. The reconstituted spray-dried
formulation elicited a highly similar immunogenicity proﬁle
as the reconstituted lyophilized formulation (Supplementary
Figure S1). Thus, in subsequent experiments, the
reconstituted spray-dried ID93+GLA-SE administered IM
was employed as a positive control to assess the
immunogenicity and efﬁcacy of the spray-dried ID93+GLASE delivered IN as a reconstituted powder, dry powder nasal
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delivery via large particle aerosol, or dry powder pulmonary
delivery via small particle aerosol.

Effect of Vaccine Delivery on Cellular
Immune Responses in the Lung and Spleen
Cytokine secretion by the host immune cells is necessary to
control Mtb infection as well as Mtb induced pathogenesis.
Previous studies have shown that IM immunization with
ID93+GLA-SE elicits a robust Th1 response in the spleen and
lung and protects upon Mtb challenge in mice and guinea pigs
(Orr et al., 2015). In contrast, IN immunization switched this
response to a Th17 response with signiﬁcant production of IL-17,
but not IFN-γ, by CD4+ T cells in the spleen and lung (Orr et al.,
2015). Here, we determined the ability of the different vaccine
delivery approaches to induce cytokine responses in the spleen
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FIGURE 5 | IM, IN, and aerosol vaccinations with ID93+GLA-SE induce cellular immune responses in vaccinated mice. B6 (n  7–8) mice were either vaccinated
with ID93+GLA-SE or only GLA-SE through intramuscular (IM), intranasal (IN), nasal aerosol delivery of large particle dry powder, or pulmonary aerosol delivery of small
particle dry powder, at day 0 and day 21. Mice spleens were harvested at 4 weeks post ﬁnal immunization and stimulated with ID93 antigen (2 μg/ml for 48 h). Levels of
splenic (A) IFN-γ and (B) IL-5 were detected in the supernatant by ELISA. Splenocyte ELISA data shown are from one experiment, and similar patterns of response
were evident in the repeat experiment. Frequency of (C) CD4+GMCSF+, (D) CD4+TNF-α+, (E) CD4+IL-17+, (F) CD4+IFN-γ+, (G) CD4+CD154+, (H) CD4+IL-5+, (I)
CD4+IL-2+, (J) CD8+GMCSF+, (K) CD8+TNF-α +, (L) CD8+IL-17+, (M) CD8+IFN-γ+, (N) CD8+CD154+, (O) CD8+IL-5+, and (P) CD8+IL-2+ T cells in the lung were
detected using ﬂow cytometry. Mice lungs were harvested at 4 weeks post ﬁnal immunization for detection of immune cell components. Flow cytometry data shown are
from one experiment and were not repeated in the second mouse experiment. For both ﬂow cytometry and ELISA readouts, responses in unstimulated controls were
subtracted from the stimulated samples, and any resulting negative values were assigned as zero. *p < 0.05, **p < 0.01, ***p < 0.001, and p < 0.0001 by one-way ANOVA
or Welch’s ANOVA with Sidak’s or Dunnet’s T3 correction, respectively, for multiple comparisons between selected groups. The Kruskal-Wallis non-parametric test with
Dunn’s correction for multiple comparisons was used when multiple comparisons were not possible with Welch’s ANOVA due to one experimental group having
constant values.
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FIGURE 6 | IM vaccination with ID93+GLA-SE induces greater serum and mucosal antibody responses than alternative routes/presentations. B6 (n  7–8) mice
were vaccinated with ID93+GLA-SE or only GLA-SE through intramuscular (IM), intranasal (IN), nasal aerosol delivery of large particle dry powder, or pulmonary delivery
of small particle dry powder, at day 0 and day 21. Antigen-speciﬁc IgA, total IgG, IgG2c, and IgG1 antibody responses in serum and bronchoalveolar lavage (BAL) were
measured 1 and 4 weeks following the second immunization by ELISA. Data presented as mean ± SD. For simplicity, all statistical differences are represented as
*p < 0.05 even when lower p-values were achieved. Each group immunized by IN or aerosol routes is compared to their adjuvant alone controls. The IM-immunized
group comparison (red asterisk) represents statistical signiﬁcance compared to all 3 alternative routes/presentations of ID93+GLA-SE. Statistical evaluation was
conducted by two-way ANOVA with Tukey’s correction for multiple comparisons between selected groups.

and lung. The immunizations were administered, as outlined in
Table 1, to C57BL/6 WT mice (14–16 mice per group) with
reconstituted spray-dried ID93+GLA-SE or GLA-SE alone (IM or
IN delivery), or ID93+GLA-SE or GLA-SE alone in spray-dried
powder form (large or small particles delivered via aerosol route).
No signiﬁcant induction of IL-17 or IL-5 cytokine in the ex vivo
stimulated splenocytes was observed for any experimental group
at 1 week post second immunization, and induction of IFN-γ was
only observed in splenocytes from mice vaccinated IM with
reconstituted ID93+GLA-SE (data not shown). At 4 weeks
post-immunization, IL-17 levels remained below detection,
whereas IFN-γ (Figure 5A) and IL-5 (Figure 5B) were
measured in mice vaccinated IM or IN with reconstituted
ID93+GLA-SE. Signiﬁcantly increased levels of IL-5 in the
supernatants were also observed from the ID93+GLA-SE large
particle nasal aerosol vaccinated group compared to
adjuvant alone.
ID93 antigen-speciﬁc cellular responses in the lung were
assessed 4 weeks post immunization. IM immunization with
ID93+GLA-SE elicited appreciable levels of a diversity of
markers including GMCSF, TNF-α, IL-17, IFN-γ, and IL-5
(Figures 5C–I). Signiﬁcantly higher induction of GMCSF,
TNF-α, IL-17, and IL-5 expressing CD4+ T cell frequencies
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was observed in mice vaccinated IN with reconstituted
ID93+GLA-SE compared to control mice receiving adjuvant
alone. Interestingly, the only signiﬁcantly upregulated CD4+
T cell marker in mice immunized with large particle
ID93+GLA-SE nasal aerosol was CD154. In contrast, mice
immunized with small particle ID93+GLA-SE pulmonary
aerosol generated signiﬁcant levels of CD4+ T cells expressing
TNF-α, IL-17, IFN-γ, and IL-2. We also determined the immune
cell activation in the CD8+ T cell compartment. Like the CD4+
T cell compartment, the data showed increased frequency of
GMCSF, TNF-α, and IL-17 expressing CD8+ T cells in the lungs
of ID93+GLA-SE small particle aerosol vaccinated groups
compared to their respective control mice 4 weeks post
immunization (Figure 5J–P). Interestingly, higher frequency
of IL-5 expressing CD8+ T cells in the lungs of ID93+GLA-SE
small particle aerosol vaccinated group was also shown as
compared to the control mice. In addition, signiﬁcantly
increased frequency of TNF-α, IL-17, and IFN-γ expressing
CD8+ T cells was observed in the lungs of ID93+GLA-SE
large particle nasal aerosol vaccinated groups compared to
their respective control mice 4 weeks post immunization.
However, unlike CD4+ T cells, there was no signiﬁcant
induction of these populations in the lungs of mice vaccinated
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control, and serum total IgG was likewise somewhat increased in
aerosol vaccine groups compared to adjuvant alone controls.
Nevertheless, no alternative immunization route/presentation
approached the level of serum antibodies elicited by IM
immunization. We also determined antigen-speciﬁc antibody
titers in the BAL samples from immunized animals. Interestingly,
we observed substantially enhanced antibody titers in mice
immunized IM with reconstituted ID93+GLA-SE at both 1 and
4 weeks post immunization, but there was no signiﬁcant elevation of
BAL antibodies in the experimental groups with the alternative
routes/presentations with the exception of slightly increased IgG1
titers in the IN-immunized group 1 week following the second
immunization. Finally, to determine the induction of long-lived
B cell speciﬁc antibody responses following immunization, we
harvested and analyzed the bone-marrow tissues (BM) of
immunized animals at 1 and 4 weeks post immunization using
antigen-speciﬁc ELISpot assay. Long-lived IgA and IgG-secreting
responses were consistently detected in the BM cells from mice
immunized IM with reconstituted ID93+GLA-SE at both time
points but not in the BM cells from mice in the other
experimental groups (Supplementary Figure S3). Overall, none
of the alternative routes/presentations approached the level of serum
antibodies, mucosal antibodies, or long-lived antibody-secreting cells
in the bone marrow induced by IM immunization. Therefore, our
data suggested an antibody-independent mechanism of protection
for mice immunized by alternative routes/presentations of
ID93+GLA-SE.

FIGURE 7 | IN delivery of reconstituted liquid ID93+GLA-SE or
pulmonary aerosol delivery of small particle size spray-dried powder
ID93+GLA-SE confers protection in a mouse model of Mtb. B6 mice (n 
18–20) were vaccinated with ID93+GLA-SE or only GLA-SE through
reconstituted liquid intramuscular (IM), reconstituted liquid intranasal (IN),
nasal aerosol delivery of large particle dry powder, or pulmonary delivery of
small particle dry powder, at day 0 and day 21. All groups of B6 mice were
rested for 4 weeks after which mice were challenged with Mtb H37Rv
(100 CFU). Mtb CFU was determined at 4 weeks post-infection. Data
presented are combined results from two identical experiments, showing
mean ± SD. *p < 0.05 and **p < 0.01 by one-way Welch’s ANOVA with
Dunnett’s T3 correction for multiple comparisons between selected groups.

Aerosol Delivery of Small Particle Size
Spray-Dried ID93+GLA-SE Confers
Protection in a Mouse Model of Mtb

IN with reconstituted ID93+GLA-SE when compared with their
respective control mice.
Some CD8+ and CD4+ T cell activity was detected even in the
adjuvant-alone groups in some readouts; therefore, the response
magnitude of vaccinated groups was interpreted with reference to
the background signal in groups receiving adjuvant alone. The
production of measurable CD8+ T cell responses as well as IL-5 by
splenocytes and CD4+ T cells in the lung following IM or IN
immunization of liquid ID93+GLA-SE are not consistent with
our previous experience (Orr et al., 2015; Kramer et al., 2018); the
cause for these discrepancies is unclear. Nevertheless, the data
suggested that reconstituted IM, reconstituted IN, and both
aerosol formulations induced differential antigen-speciﬁc
cellular immune response proﬁles in the lung, whereas the
small particle pulmonary aerosol formulation did not elicit
measurable cytokine responses in the spleen.

IM immunization with liquid or reconstituted lyophilized
ID93+GLA-SE elicits a robust Th1 response and limits Mtb in
animal efﬁcacy models (Kramer et al., 2018). Furthermore, we
previously demonstrated that IN immunization with liquid
ID93+GLA-SE is as efﬁcacious as the IM route of the vaccine
(Orr et al., 2015). The immunizations were administered, as
outlined in Table 1, to C57BL/6 WT mice (8–10 mice per
group) with reconstituted spray-dried ID93+GLA-SE or GLASE alone (IM or IN delivery), or ID93+GLA-SE or GLA-SE alone
in spray-dried powder form (large or small particles delivered via
aerosol route), followed by challenge with Mtb H37Rv. The lung
bacterial burden following pulmonary aerosol delivery of smaller
particle size spray-dried ID93+GLA-SE was observed to be
signiﬁcantly lower than with the adjuvant alone (Figure 7).
The level of protection in the lungs derived from the smaller
particle size spray-dried powder ID93+GLA-SE was comparable
to the reconstituted vaccine delivered as a liquid via the IM or IN
routes of delivery. Immunization via nasal aerosol delivery of the
larger particle size spray-dried powder ID93+GLA-SE did not
cause a reduction in lung bacterial burden compared to adjuvant
alone. However, the level of mean lung CFUs among the four
experimental groups administered ID93+GLA-SE was similar
and, for the statistically signiﬁcant differences shown in
Figure 7, represented a 0.2–0.4 log reduction in CFUs
compared to the experimental groups administered GLA-SE

Effect of Vaccine Delivery Method on
Antibody Responses
We measured the levels of antigen-speciﬁc antibodies in the
serum following immunization and observed that mice that
were vaccinated IM with reconstituted ID93+GLA-SE had the
highest magnitude of antibody titers for all isotypes measured at both
1 and 4 weeks post immunization (Figure 6). Serum total IgG,
IgG2c, and IgG1 levels were slightly elevated in mice vaccinated IN
with reconstituted ID93+GLA-SE compared to the adjuvant alone
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alone. In our previously published experiments using similar
mouse challenge models with lyophilized ID93+GLA-SE or other
recombinant protein or DNA vaccines, immunized animals
tended to reduce lung CFU burden by 0.4–1 log compared to
unvaccinated controls, where mean log CFU levels in the lung for
control mice were ∼4.7–5.3 for this challenge system (Orr et al.,
2013; Gopal et al., 2014; Orr et al., 2014; Grifﬁths et al., 2016b;
Ahmed et al., 2017a; Ahmed et al., 2017b). There were no
signiﬁcant differences observed in spleen bacterial burden
among the groups of mice infected with Mtb, although the
lowest mean bacterial burden was associated with spray-dried
pulmonary aerosol delivery (Supplementary Figure S4). In
summary, these results demonstrated that the spray-dried
pulmonary aerosol vaccine delivery and the liquid IN vaccine
delivery resulted in signiﬁcant protective efﬁcacy against Mtb
challenge compared to adjuvant alone delivered by the
same route.

particle C1 formulation, which targeted deposition in the nose
only. Higher system efﬁciency of the former is likely due to the
smaller particle size as larger particles are expected to deposit due
to inertial impaction or sedimentation as the aerosol traverses the
aerosol system. Optimization results also demonstrated that the
constrictions on tolerable duration of exposure and aerosol
concentration at the noseports limited the possible amount of
powder that could be delivered to the mice. Therefore, the active
components of experimental vaccines needed to be concentrated
above intended clinical dosage to achieve the target dose in
preclinical aerosol studies.
The system efﬁciencies of the small and large particle vehicles
are a clear improvement over a recent study that delivered
nebulized bacteriophage-containing droplets to mice using an
aerosol system consisting of a vibrating mesh nebulizer and the
NOID characterized in this study (Carrigy et al., 2019). Those
experiments were run with an aerosol ﬂow rate of 500 ml/min
and the overall system efﬁciency was only 1.50% of the nominal
dose measured on the exit ﬁlter and 0.033% of the nominal dose
measured at the noseports under optimized processing
parameters (Carrigy et al., 2019). Conversely, the current study
demonstrated that 8.9 and 40.0% of the nominal dose were
measured on the exit ﬁlter for the large particle vehicle and
small particle vehicle, respectively. Improved system efﬁciency is
likely due to the engineered properties of the particles that
resulted in high aerosol performance, as well as possible reentrainment within the system.
A lower delivered dose relative to the nominal dose was
measured in this study, with approximately 0.024 and 0.11%
estimated to be inhaled at the noseports for the small particle
vehicle and large particle vehicle under optimized conditions,
respectively. However, this low relative nominal dose can be
attributed to the necessary higher aerosol ﬂow rate of 8.33 L/min
required to operate the aerosol delivery device used in this study.
Due to the difference between aerosol ﬂow rate and the total
inhalation rate of the mice, approximately 97% of aerosol
available will bypass the mice. Consequently, even in an ideal
system with no losses, the maximum dose delivered to each
mouse in a 12-mouse experimental set up would be only
0.25% of the nominal dose. Therefore, delivered dose was
approximately 10 and 44% for the C1 and C2 formulations
under optimized conditions, respectively, relative to the
maximum possible delivered dose. The difference in the
estimated delivered dose versus maximum possible dose was
accounted for by engineering higher concentrations of active
ingredients ID93 and GLA to ensure delivered doses of these
components were approximately equivalent regardless of route.
Nevertheless, it is possible that the actual delivered dose of
antigen and adjuvant varied from these estimates, which could
impact the immunogenicity and efﬁcacy results.
The size distribution of the C1 and C2 powders measured at
the outlet of the aerosol system was close to the target of ∼5 μm
and 1–2 μm, respectively. These dispersion results suggest that
the chosen operating parameters of a high brush speed, low
powder feed ﬂow rate, and low aerosol ﬂow rate were suitable for
dispersing the powder. However, the powders tested in this study
were designed to be easily dispersible due to the accumulation of

DISCUSSION
Pulmonary TB continues to persist as a global pandemic due to
the lack of an effective human vaccine for over a hundred years
since the implementation of the only licensed BCG vaccine
(Colditz et al., 1994). Complications from the current COVID19 pandemic in combination with the already existing emergence
of drug-resistant strains of Mtb have further heightened the
spectre of TB. The respiratory tract is the natural route of Mtb
infection. Therefore, when compared with traditional parenteral
routes of vaccination, there is general agreement that mucosal
vaccination induces superior protection against Mtb challenge
(Goonetilleke et al., 2003; Chen et al., 2004; Wang et al., 2004;
Santosuosso et al., 2005; Perdomo et al., 2016; Mata et al., 2021;
Ning et al., 2021). The successful formulation and manufacture of
the prophylactic TB vaccine (ID93) co-lyophilized with the GLASE oil-in-water emulsion adjuvant produced a thermostable,
single-vial candidate product that is being evaluated in an
ongoing clinical trial as a reconstituted IM vaccine (Kramer
et al., 2018). We further developed the same vaccine as a
thermostable spray-dried powder to aid in bulk storage and
mucosal delivery for improved utility in clinical ﬁeld
applications (Gomez et al., 2021a; Gomez et al., 2021b; Gomez
et al., 2021c). In this study, we evaluated the immunogenicity and
efﬁcacy of the spray-dried ID93+GLA-SE powder delivered as an
inhaled aerosol either to the nose and lungs (pulmonary delivery)
using smaller particle size spray-dried formulations, or to the
nose (nasal delivery) using larger particle size spray-dried
formulations, compared to the reconstituted liquid vaccine
administered
intranasally
or
by
the
conventional
intramuscular route.
Development and characterization of an aerosol system is
critical for successful vaccine-inhalation animal studies.
Optimization experiments with the vehicle-only powder
formulations demonstrated that delivery efﬁciency was
improved with reduced powder feed rate. The small particle
C2 formulation, targeting deposition in the nose and lungs of
mice, achieved a much higher system efﬁciency than the larger

Frontiers in Pharmacology | www.frontiersin.org

17

January 2022 | Volume 12 | Article 799034

Gomez et al.

Spray-Dried Tuberculosis Vaccine Candidate

(Derrick et al., 2014). Higher frequencies of CD4+ T cells
expressing gamma interferon (IFN-γ) and IFN-γ/TNF-α, as
well as CD8+ T cells expressing IFN-γ, were detected in the
spleens of intranasal BCG vaccinated mice. Recent studies in
macaques have shown that mucosal or intravenous BCG better
protects rhesus macaques from Mtb infection and TB disease
than standard intradermal vaccination, correlating with local
adaptive immune signatures (Vierboom et al., 2021).
Moreover, Th17 cells that produce IL-17 play a critical role as
primary effector cells mediating vaccine-induced protection
against Mtb (Khader et al., 2007; Gopal et al., 2013; Grifﬁths
and Khader, 2014; Aguilo et al., 2015; Monin et al., 2015;
Counoupas et al., 2020). In the current study, we found that
the pulmonary aerosol delivery of the spray-dried vaccine
provided protection against Mtb challenge compared to
adjuvant alone. The pulmonary-delivered vaccine also elicited
increased levels of both IFN-γ and IL-17 responses by CD4+
T cells in the lung compartment; however, it did not elicit
appreciable serum or mucosal antibody responses. Indeed,
little or no antibody responses were elicited in all groups
immunized by the mucosal routes, possibly indicating antigen
degradation or conformational alteration following mucosal
administration. While the role of antibodies in protection
against Mtb is unclear (Jacobs et al., 2016), the importance of
cell-mediated immunity is well-established. Although
immunization via nasal aerosol delivery of the larger particle
size spray-dried powder ID93+GLA-SE did not cause a reduction
in lung bacterial burden compared to adjuvant alone, it is unclear
whether the lung CFU levels of the adjuvant alone group in this
case were associated with a non-speciﬁc protective effect or
whether this could be attributable to experimental variation.
In previous studies, we have demonstrated that localization of
vaccine-induced CD4+ T cells within parenchyma and activation
of myeloid cells promoted the formation of protective lymphoidcontaining granuloma structures within the lung and the control
of Mtb replication (Das et al., 2021). Mtb is considered as a
successful pathogen for its ability to escape host immune
responses efﬁciently. Studies have demonstrated that, following
Mtb infection, delay in the activation of antigen-speciﬁc CD4+
T cell responses occurs likely due to Mtb’s ability to directly
inhibit MHC-II transactivator expression, MHC–II expression,
and antigen presentation (Harding and Boom, 2010). BCG
vaccination can generate systemic vaccine-induced T cell
responses. Our recent work demonstrates that rapid
ampliﬁcation of early CD4+ T cell response and localization
within airway and parenchyma compartments in the lung is
necessary for superior vaccine induced immunity (Das et al.,
2021). Similar response is seen in non-human primates
vaccinated intravenously with BCG, where the heightened and
lung-localized T resident memory (Trm) cells are considered to
be a mechanism through which complete control of Mtb infection
is mediated (Darrah et al., 2020). Based on our current study, we
expect that delivery of spray-dried IN and dry powder aerosol
vaccinations can induce activation of antigen-speciﬁc T cells in
the lymph nodes and possibly recruitment to the lung. Thus, our
results, along with recent reports including intravenous (Darrah
et al., 2020) and mucosal BCG use (Verreck et al., 2017), suggest

trileucine on the surface. System efﬁciency and dispersion
capability is strongly dependent on the particle size, surface
composition, and surface morphology.
Previous work developing spray-dried versions of the
ID93+GLA-SE vaccine (Gomez et al., 2021a; Gomez et al.,
2021b; Gomez et al., 2021c) led to successful manufacturing of
the formulations for the mouse model. The formulations
designed for delivery upon reconstitution were prepared
without trileucine whereas the formulations designed for
aerosolized delivery included trileucine as a dispersibility
enhancer. Further discussion on the inclusion of a
dispersibility enhancer to improve aerosol performance of a
powder can be found elsewhere (Gomez et al., 2021b). The
powders without trileucine formed smooth particles primarily
composed of trehalose. These powders are expected to exhibit
poor aerosol performance due to their smooth surface
morphology. By contrast, the trileucine-containing particles
demonstrated rugose surface morphology. This change in
surface morphology due to the inclusion of trileucine has been
previously shown to improve aerosol performance (Gomez et al.,
2021b). The nanoemulsion diameter, size polydispersity index,
squalene content, and GLA content were within target for all
spray-dried formulations with the exception of the V-D-N and
V-D-NL lots that were above the size polydispersity index target.
These lots both include trileucine and the ID93 antigen. Previous
work has suggested that inclusion of trileucine increases
nanoemulsion droplet diameter and polydispersity index
(Gomez et al., 2021c). However, the acceptance criteria for
polydispersity index were originally based on a dosage form
designed for reconstitution and injectable delivery (Kramer
et al., 2018), and it is likely that this parameter is not
meaningful for an inhaled administration route that does not
require reconstitution. A more important parameter to address is
the antigen content since ID93 processing loss was variable,
indicating that further work is needed to optimize spray
drying of the ID93 antigen.
When compared to systemic routes of immunization, mucosal
vaccines induce better immunity and confer superior protection
against mucosal infectious diseases, including TB (Goonetilleke
et al., 2003; Chen et al., 2004; Wang et al., 2004; Santosuosso et al.,
2005; Neutra and Kozlowski, 2006; Perdomo et al., 2016; Ahmed
et al., 2017a; Ahmed et al., 2017b). Mucosal delivery of vaccines
promotes both systemic and mucosally localized adaptive
immune responses, whereas parenteral immunization primarily
programs systemic immunity. BCG or MVA85A (or as a booster
to BCG) delivered by intradermal injection both elicit Th1
responses (Tameris et al., 2014). The gold-standard vaccine
BCG protects against disseminated childhood TB, but
protection against lung TB in adolescents and adults is
variable and mostly poor. MVA85A administered as a booster
to BCG was safe but not effective in reducing the risk of
developing TB (Tameris et al., 2013; Kashangura et al., 2019).
Interestingly, intranasal BCG vaccination has been reported to
provide short-term enhancement of protection in the lung
relative to subcutaneous immunization, with potent and
extremely persistent splenic protective responses lasting for
10 months following respiratory immunization in mice
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that generating a lung-resident activated T cell pool is a good
strategy for improving vaccine-induced immunity against TB.
However, we also consider the possibility of local proliferation of
T cells following aerosol vaccination in this study.
During Mtb infection, recognition of infected macrophages
in the lung by CD4+ effector T cells is required for intracellular
Mtb control (Srivastava and Ernst, 2013). Therefore,
localization of Trm CD4+ T cells in the lung is an important
event required for Mtb control. In human studies, CXCR5+
CCR5+ T cells in the lungs and pleural ﬂuid produced IFN-γ
(Lindestam Arlehamn et al., 2013; Perreau et al., 2013; Saha
et al., 2013), a signature Th1 response. Moreover, in the
preclinical macaque model of latent and active TB,
CXCR3+CCR6+ co-expressing T cells produced both IL-17
and IFN-γ cytokines in the BAL and were associated with
the protective responses in latent TB (Shanmugasundaram
et al., 2020). Finally, in vaccine models of subunit
vaccination, CD4+ T cells that were able to readily trafﬁc to
the lung parenchyma, provided Mtb control in vivo
(Woodworth et al., 2017). Both IFN-γ and IL-17 have
different roles in controlling Mtb following vaccination.
While recent data have shown that IFN-γ (Gopal et al., 2013)
and IFN-γ produced by CD4+ T cells (Sallin et al., 2017) are
considered redundant, IL-17 is necessary for vaccine-induced
control in many models of vaccination (Khader et al., 2007;
Gopal et al., 2012; Kumar et al., 2016). More recent work from
our lab has also demonstrated a critical combined role for IL-17/
IL-22 and IFN-γ in conferring early vaccine-induced control of
Mtb infection (Das et al., 2021). Therefore, it is likely that the
mucosal delivery of vaccine to the lung can accelerate
parenchymal homing of antigen-speciﬁc CD4+ T cell subsets
to gain access to the Mtb-infected cells within the granuloma
and reduce Mtb replication through activation of signaling
involving both the Th1/Th17 cytokine axis along with other
mediators.
There are several limitations to the current study. Although
tetramer-based staining and draining lymph node T cell
responses were evaluated in the initial immunogenicity
experiment
(Supplementary
Figure
S1),
subsequent
immunogenicity experiments did not include tetramer-based
staining or assess lymph node activity due to practical limitations
such as experimental throughput and cell viability based on the
number of mice and other assays to be performed. For similar
considerations, and based on previous experience that lung bacterial
burden in animals administered saline alone was indistinguishable
from lung bacterial burden in animals administered GLA-SE alone
(Bertholet et al., 2010), saline or non-vaccinated control groups were
not included in the protective efﬁcacy experiments reported here.
Nevertheless, it cannot be ruled out that GLA-SE administered by
alternative routes results in non-speciﬁc effects in the efﬁcacy results
shown here.

a dry powder, was compared within a mouse model for the
spray-dried TB vaccine ID93+GLA-SE. A custom-built aerosol
delivery system was used for the inhalation component of the
study. This system consisted of two main components: a dust
generator to aerosolize the spray-dried vaccine and a noseonly inhalation device to restrain the mice and deliver the
aerosolized dry powder vaccine. The aerosol delivery system
parameters were optimized using two control formulations: 1)
a formulation that would target nose-only deposition and 2) a
formulation that would target nose and lung deposition in
mice. Experiments with both formulations showed that the
designed system greatly outperformed the aerosol delivery
efﬁciency of a similar set up and was capable of dispersing
the spray-dried powder to a particle size suitable for inhalation
by mice.
The pre-clinical experiment design consisted of seven
experimental groups that would immunize mice with
either the spray-dried vaccine or an adjuvant-alone spraydried powder as a negative control. These experiments were
also designed to compare different routes of delivery,
namely, IM injection, IN delivery of a reconstituted
liquid, nasal delivery of a dry powder, and pulmonary
delivery of a dry powder. Different formulations and spray
drying parameters were used for manufacturing the powder
for the different experimental groups based on the route of
delivery. Analysis of the powder found that particle
morphology for each lot was as expected. The
physicochemical integrity of all formulations was also
assessed after spray drying in terms of nanoemulsion
droplet size distribution, squalene content, GLA content,
and ID93 content. Results showed that the different
formulations were either within or close to target,
demonstrating that spray drying is a viable method of
vaccine desiccation. This conclusion was further
conﬁrmed through the similar immune responses
generated by the reconstituted spray-dried vaccine to the
reconstituted lyophilized presentation when administered
IM in a mouse model.
Our results show that both IN liquid vaccine delivery as well
as pulmonary dry powder vaccine delivery resulted in Mtb
control in infected mice. Additionally, improved protection in
these two vaccinated groups over their respective control
groups coincided with the presence of cytokine-producing
T cell responses, whereas antibody responses in all groups
were substantially reduced compared to IM immunization.
Our results demonstrate that spray-dried ID93+GLA-SE
administered by IM or alternative routes elicits protective
efﬁcacy against Mtb infection. While pulmonary dry powder
vaccine delivery did not improve upon the levels of protective
efﬁcacy of the liquid vaccine administered IM or IN, the dry
powder formulation offers practical advantages including
enhanced stability and simplicity of administration that
does not require needles nor reconstitution. Even for
reconstituted injectable vaccines, a spray-dried powder may
offer cost and scalability advantages compared to a lyophilized
cake (Gomez et al., 2021a). In addition, these results highlight
the importance of a rational approach based on formulation

CONCLUSION
The administration routes of IM injection, IN delivery of a
liquid, IN delivery of a dry powder, and pulmonary delivery of
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and engineering principles for the development of spray-dried
powder vaccines, taking into account the practical limitations
and complexity of testing such formulations in small animal
experimental models. Finally, these results motivate further
development of spray-dried ID93+GLA-SE powder to assess
immunogenicity and efﬁcacy in large animal models with
greater relevance to humans in terms of anatomy and Tolllike receptor expression.
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